Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Documenti analoghi

• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
  di: Sara A. Scott, et al.
  Pubblicazione: (2023-12-01)
• Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
  di: Lorenzo Cani, et al.
  Pubblicazione: (2025-09-01)
• Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
  di: Sayalee V. Potdar, et al.
  Pubblicazione: (2025-05-01)
• Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients
  di: Nisha S. Joseph, et al.
  Pubblicazione: (2024-09-01)
• Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity
  di: Alberto Moreno, et al.
  Pubblicazione: (2024-10-01)